Summarized by Masters of Longevity from Longevity Technology.
Reports present peer-reviewed data linking an oral anti-amyloid drug to sustained reductions in blood biomarkers and associated clinical measures in early Alzheimer’s patients.
Key Takeaways
- Plasma p-tau217 levels were significantly lower on valiltramiprosate versus placebo at weeks 26, 52, and 78 in the Phase 3 population.
- Patients with larger p-tau217 declines by week 78 showed smaller cognitive and functional declines and less hippocampal atrophy.
- Neurofilament light chain remained stable on treatment while it rose on placebo, and no ARIA-E brain swelling cases were reported on the drug.
